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Abstract: Developmental exposure to neurotoxic chemicals presents significant health 
concerns because of the vulnerability of the developing central nervous system (CNS) and 
the immature brain barrier. To date, a short list of chemicals including some metals have 
been identified as known developmental neurotoxicants; however, there are still numerous 
chemicals that remain to be evaluated for their potential developmental neurotoxicity (DNT). 
To facilitate evaluation of chemicals for DNT, the zebrafish vertebrate model system has 
emerged as a promising tool. The zebrafish possesses a number of strengths as a test 
species in DNT studies including an abundance of embryos developing ex utero presenting 
ease in chemical dosing and microscopic assessment at all early developmental stages. 
Additionally, rapid neurodevelopment via conserved molecular pathways supports the 
likelihood of recapitulating neurotoxic effects observed in other vertebrates. In this review, 
we describe the biological relevance of zebrafish as a complementary model for assessment 
of DNT. We then focus on a metalloid and two metals that are known developmental 
neurotoxicants (arsenic, methylmercury, and lead). We summarize studies in humans and 
traditional vertebrate models and then detail studies defining the toxicity of these 
substances using the zebrafish to support application of this model system in DNT studies. 








Developmental exposure to certain chemicals are suggested as possible causes of neurodevelopmental 
impairments including reduced intelligence quotient (IQ), autism spectrum disorder (ASD) and 
attention deficit hyperactivity disorder (ADHD) [1–4]. The particular susceptibility of the developing 
central nervous system (CNS) has been noted for decades and several publications suggest that there 
might be a critical window of exposure during brain development [5–8]. It has also been discussed that 
early-life stimulation via environmental stressors such as chemical exposures may trigger genetic or 
epigenetic changes that modulate an organism’s biological system, which in turn leads to 
neurodevelopmental alterations [7,9–11]. Thus, exposure of early-life organisms to certain chemical 
compounds, especially during the critical period of development including prenatal and early postnatal 
stages, can have significant adverse impacts on the process of CNS development. In addition, some 
characteristics of neurodevelopmental disorders (e.g., those associated with ADHD and ASD) can 
continue into adulthood, implying the adverse effects of a childhood neurodevelopmental alteration can 
influence health throughout the lifespan [12,13]. 
To date, several chemicals including some metals and their related compounds are noted as 
neurotoxicants (reviewed in [14,15]). However, currently there is insufficient evidence to prove 
developmental neurotoxicity (DNT) for the majority of chemicals with only a few of them  
(e.g., arsenic, methylmercury, and lead) reported as known developmental neurotoxicants (reviewed  
in [14,15]). Environmental contamination of arsenic, methylmercury, and lead is widespread, resulting 
in frequent human exposure raising public health concerns (reviewed in [16–20]). These toxicants are 
non-biometals that do not play a role in biological systems and have been associated with 
neurodevelopmental alterations in developing organisms [3,21–23]. 
The little progress in identifying the DNT of chemicals is in part due to the limitation of studies 
using conventional in vivo models (e.g., non-human primates and rodent models), of which 
experiments are laborious, time-consuming, and may not be cost-effective. To this end, the zebrafish 
model system has emerged as a suitable complementary in vivo DNT test model. This model system 
has been applied historically as a powerful in vivo tool for developmental biology studies with 
numerous strengths as a laboratory test animal. The embryonic developmental stages of zebrafish are 
well documented, which provides a guide for researchers to identify major physiological alterations 
occurring during developmental toxicity assays [24]. Moreover, there is continuous progress on 
uncovering the developmental processes of the CNS and blood-brain-barrier (BBB) of the  
zebrafish [25–30]. Overall development of the zebrafish CNS and patterning of brain sub-regions are 
completed within three days after fertilization during which neurogenesis and formation of pioneer 
axons initiate (Figure 1). The rapid CNS development coupled with the general strengths of the 
zebrafish model system allows screening of chemical compounds for potential DNT, resulting in the 
zebrafish being an ideal complementary model for DNT studies. 
In this review, the general merits and biological significance of the zebrafish as a DNT test model 
are described. We then summarize DNT studies of a known metalloid and two metal neurotoxicants 
(i.e., arsenic, methylmercury, and lead) in humans and traditional vertebrate models. Moreover, we 
introduce research studies utilizing the zebrafish for DNT assessment of various chemicals and also 
show potential of the zebrafish as an in vivo model for rapid chemical-induced DNT screening. Finally, 
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we discuss progresses made in studies on the DNT of arsenic, methylmercury, and lead using the 
zebrafish to support the application of this model system in DNT studies. 
Figure 1. Zebrafish neurodevelopment. (a) At 72 h post fertilization (hpf) major 
subdivisions of the zebrafish brain are present; Zebrafish axonal networks visualized by 
acetylated α-tubulin staining (b) at 72 hpf, (c) at 96 hpf, and (d) at 120 hpf of development. 
Scale bar = 100 µm. (C, cerebellum; H, hindbrain; M, midbrain; F, forebrain). 
 
2. Zebrafish as a Model for DNT 
2.1. General Strengths of the Developmental Zebrafish Model System 
The zebrafish model system has long been applied in the field of developmental biology [31–35]. 
Over the past decade, the zebrafish has also emerged as a popular tool for investigating the 
neurotoxicity of drugs and environmental chemicals [36–66]. The zebrafish presents numerous 
strengths as an in vivo test model including ex utero fertilization and transparency of embryos  
and early larvae, enabling microscopic observation through early developmental stages. The ex utero 
embryonic development also eases the determination of doses of exposed chemicals at all embryonic 
stages, providing explanation of exposure kinetics of chemicals of interest [67–70]. Moreover, the 
rapid growth and high fecundity of zebrafish facilitate higher throughput toxicity testing of multiple 
chemicals. In addition, a high degree of genetic similarity (≈70%) with humans allows application of 
zebrafish for human disease genetic studies [71]. The fully sequenced zebrafish reference genome, 
combined with the ability to use reverse genetic approaches, eases mechanistic studies on chemical 
toxicity using this species. The similarity of neural development between the zebrafish and other 
vertebrates also supports the application of the zebrafish as a complementary research tool to 
conventional vertebrate models for DNT assays [25,28,72]. There is also biological similarity between 
the zebrafish and other vertebrates in the development and function of biological barrier systems in the 
developing CNS (i.e., the BBB). The BBB is one of the most effective barrier systems in vertebrates 
and it is generally accepted that the BBB plays a pivotal role in the protection of the brain against 
neurotoxic insults. While there are many similarities, there are also some differences between the 
development of the zebrafish and mammalian brain. These similarities and differences are  
discussed below. 
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2.2. Comparison of Mammalian and Zebrafish CNS Development 
Following fertilization in vertebrates, the newly formed embryo undergoes several cycles of rapid 
cell division, during which a blastula (i.e., a single-cell organism) transforms into an embryo at the 
gastrula stage (i.e., a multi-cell organism). During gastrulation, three germ layers including the 
endoderm (the interior germinal layer), ectoderm (the outside germinal layer), and mesoderm are 
formed. The ectoderm, specifically the neuroectoderm, gives rise to the CNS (reviewed in [25,28]), 
whereas the endoderm and mesoderm are involved in the development of other organs (e.g., the kidney, 
liver, and pancreas) and tissues (e.g., bone and connective tissue). The neuroectoderm specifies to the 
neural plate, the origin of the CNS. The formation of the neural plate is followed by the neurulation 
process, in which the neural plate folds to generate the neural tube (reviewed in [25,28]). The neural 
tube eventually forms major components of the CNS including the brain, spinal cord, and nerves. 
Similar to the general processes of vertebrate neurogenesis, development of the zebrafish CNS also 
begins with the specification of the neuroectoderm and generation of the neural plate. At this point, the 
zebrafish embryo undergoes a slightly different process from general vertebrate neurulation. Unlike 
most vertebrates, which directly generate the neural tube by neural plate folding, the zebrafish converts 
the neural plate to the neural keel, which then forms the neural rod and then the neural tube [28,73]. 
The arrangement of critical divisions of the brain proceeds during gastrulation. In the zebrafish, 
gastrulation occurs from 5.25–6 to 10 h post fertilization (hpf), during which precursors of the 
forebrain and other regions (i.e., the midbrain, hindbrain, and spinal cord) proceed toward the anterior 
and more posterior positions, respectively [24,30]. Zebrafish primary neurons appear by  
24 hpf, forming simple neuronal clusters in neuromeres (reviewed in [74]). During early 
embryogenesis, there are only a few axonal tracts and commissures, but with the initiation of axonal 
projections by the primary neurons complex neuro-networks throughout the body through later 
developmental stages are gained (Figure 1b–d) [74–78]. The morphological development of major 
organ systems nears completion at the end of embryogenesis (≈72 hpf) with the BBB present at an 
earlier stage [24,29]. 
2.3. Blood-Brain Barrier (BBB) in the Zebrafish 
The BBB is composed of endothelial cells on cerebral blood capillaries. The BBB protects the brain 
from toxicants by preventing free-transport of substances. The filtering function of the BBB occurs by 
endothelial cells connected through tight junctions restricting free movement of ions or solutes  
(e.g., toxicants and macromolecules) between inside and outside of the barrier (reviewed in [79]). The 
BBB also isolates neurotransmitters and neuroactive substances in the CNS from those in the 
peripheral nervous system, hindering the interaction between the two systems (reviewed in [79–81]). 
Most water soluble substances are not able to freely enter the BBB because the tight junctions that 
connect nearby endothelial cells limit the movement of hydrophilic solutes through paracellular 
networks [79,82]. However, substances with low molecular weight or lipophilic characteristics can 
diffuse through the transmembrane relatively easy, implying that the BBB is not an absolute barrier 
against neurotoxic chemicals [83,84]. 
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Although the BBB may play a significant role in understanding the influence of exposure to 
neurotoxic substances on the developing brain, the functional mechanism and the maturation process 
still remain to be elucidated. It has been a generally accepted notion that the formation of the BBB is 
not complete during early developmental stages; in humans, it is not until the age of 6 months, during 
which the young brain still undergoes critical development up until 2 years of age [85–87]. However, 
this assumption of the immature BBB has been challenged with increasing evidence showing that the 
BBB appears at very early developmental stages and that proteins involved in BBB formation and also 
functional tight junctions exist in the developing brain (reviewed in [88–90]). There are several 
important players involved in the BBB junctional complex activity that maintains the homeostasis of 
the brain including two tight junction proteins: Claudin-5 and Zona occludens protein 1 (ZO-1) [91–96]. 
The genes encoding these proteins in humans (CLDN5 and TJP1, respectively) and in mice (Cldn5 and 
Tjp1, respectively) are also found in zebrafish as cldn5a and cldn5b, and as tjp1a and tjp1b [97–101]. 
The presence of the BBB in zebrafish at early life stages became evident by Umans and  
Taylor [29] when a drug transporter protein (i.e., multidrug resistance protein 1) at the BBB was 
immunohistochemically visualized at 48 hpf. While the exact timing of complete maturation of 
zebrafish BBB is unclear, it has been revealed that two tight junction proteins, Claudin-5 and ZO-1, in 
zebrafish brain endothelial cells are expressed as early as 72 hpf [27]. As visualized by Jeong et al. [27], 
the BBB of zebrafish is functional at 72 hpf as the leakage of an injected large molecular weight tracer, 
rhodamine-dextran (10 kDa) was restricted in microvessels of brain parenchyma. The zebrafish BBB 
may undergo further maturation to exclude small molecules after completion of embryogenesis,  
as shown in Fleming et al. [102] with the inclusion of Evans blue (961 Da) and sodium fluorescein 
(376 Da), restricted through 5 and 10 days after fertilization, respectively. 
Due to the vulnerability of the developing CNS and limited information about the BBB function of 
organisms at early life stages, a developmental exposure to environmental chemicals raises significant 
concerns for potential detrimental effects to the CNS and contribution to neurodevelopmental disorders. 
To date, a short list of chemicals including some metals and metalloids (e.g., arsenic, methylmercury, 
and lead) are identified as known developmental neurotoxicants (reviewed in [14,15]). In the sections 
below, we summarize the developmental neurotoxic effects of these toxicants as observed in humans 
and in traditional in vivo vertebrate animal models. We also introduce studies on various chemicals 
subjected to DNT testing using the zebrafish model. We then detail studies that have used the zebrafish 
model system for DNT assessment of arsenic, methylmercury, and lead. 
3. DNT of Arsenic, Methylmercury, and Lead 
3.1. Arsenic 
Arsenic is a metalloid element existing in nature, which can be found in an inorganic or organic 
form with several oxidation states, including trivalent arsenic (arsenite) and pentavalent arsenic 
(arsenate). Exposure to arsenic raises health concerns as it can damage our body by interacting with 
biomolecules and produce reactive oxygen species (reviewed in [103]). Arsenic has a long history of 
use as a pesticide, food preservative, and cancer chemotherapeutic agent (reviewed in [103]). Although 
the application of arsenic in the production of pesticides and food preservatives has mostly  
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been phased out, human exposure to arsenic still occurs because of the widespread environmental 
contamination and natural presence in geological stores in some regions of the globe [18,19,104–108]. 
Epidemiological studies report a number of arsenic exposure cases through contaminated drinking 
water supplies. Global epidemiological studies report a close relationship between early-life arsenic 
exposure and intellectual/cognitive ability of school-aged children [109–112]. For example, in a recent 
study conducted in the United States (US), Wasserman et al. [112] investigated the association of 
arsenic exposure through drinking water at home and the IQ levels of 272 school-aged children  
(mean age of 9.67-years) with the mean residence time in the current dwelling place (~7.34 years). 
Researchers compared the IQ of children exposed to low levels of arsenic (arsenic concentrations in 
water below 5 µg/L) to the IQ scores of those exposed to high levels of arsenic (arsenic concentrations 
in water between 5–10 µg/L). In participants exposed to high levels of arsenic, there was a significant 
decrease in the overall intellectual ability with about a six-point decrement in full scale IQ [112]. 
When tested with younger aged groups, however, the adverse effects of arsenic exposure on 
children’s intellectual development becomes inconclusive [109,113]. For example, Nahar et al. [109] 
and Hamadani et al. [113] examined the association of children’s IQ levels with urinary arsenic 
concentrations obtained from the participants at the age of 4 and/or 5 years. In the study of  
Nahar et al. [109], researchers found an association between arsenic concentration in urine and a 
significant decrease in non-verbal IQ levels, but not in verbal IQ. On the other hand, Hamadani et al. [113] 
found a significant negative relationship between the urinary arsenic levels and verbal as well as full 
scale IQ of female children at 5 years of age. 
There are also studies completed on infantile neurodevelopment in relation to prenatal arsenic 
exposure. According to two recent birth cohort studies, the impact of arsenic exposure on early 
neurodevelopment may not be identical in infants at different ages [114,115]. When a study was 
conducted with 1-day old infants, researchers did find a negative relationship between the arsenic 
levels measured in cord blood and the neurodevelopmental status of newborns when evaluated by 
Brazelton Neonatal Behavioral Assessment Scale (III) [115]. However, this negative relationship did 
not appear in a more recent study with neurodevelopment evaluated by the Bayley Scale of Infant 
Development (II) using a cohort of 6-month old infants [114]. 
Rodent studies have reported reproducible results showing neurobehavioral and neurophysiological 
alterations following a developmental arsenic exposure continuing over different periods of time [116–118]. 
In studies conducted under sub-chronic or chronic exposure conditions, rats treated with arsenite from 
early gestation exhibited behavioral changes with impaired learning/memory ability [117,118]. For 
instance, rats treated with 36.7 mg/L arsenite from gestation day (GD) 15 through 4 months of age 
exhibited significant alterations in spontaneous locomotion and poor performance in the delayed 
alternation test [117]. In addition, more recent studies with shorter exposure periods (e.g., arsenite 
exposure beginning in early gestation until weaning) show molecular-level changes occurring in the rat 
brain, including reduced enzymatic antioxidant activity and altered expression of neural cell adhesion 
molecules [116,119]. Studies conducted in the past five years on the neurotoxic effects of arsenic 
exposure with rodent models in developmental stages are summarized in Table 1. 
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Table 1. A selection of studies carried out over the past five years on the neurotoxic effects of arsenic, MeHg, or Pb exposure in the zebrafish 
or in vivo rodent models during developmental stages. 




Zebrafish 2 mM 4–48 hpf 
Altered axon outgrowth in the brain and nerve growth in 
the spinal cord 





13.6 mg/L  
(≈0.1 mM) GD0–PND21 Delayed behavioral development (reflex responses) 
Luo et al. 
[116]  
10 mg/L  
(≈0.08 mM)  
or above 
GD6–PND42 Altered reflex responses or learning/memory behaviors 
Xi et al. 
[118] 
Zebrafish 
2 mM  
or above 
4–30 hpf 
Decrease in reflexive movement frequency under  
light stimulation 






0.1 mg/kg  
(≈0.5 µM)  
or above 
GD6–PND10 
Altered expression of genes related to brain 
development functional cluster in female offspring brain 
Radonjic  
et al. [121] 
Mouse 
4 mg/kg  
(≈0.02 mM) 
for 9 weeks including 
gestation period and  
2 weeks post-partum 
Altered expression of genes related to functional classes 
of cell morphology/function, growth factor activity, or 
receptor binding in pup brain 
Jayashankar 
et al. [122] 
2.6 mg/kg  
(≈0.01 mM) 
for 8 weeks including 
gestation period and  
2 weeks post-partum 
Altered expression of genes enriched in cell proliferation 
or stress response functions in pup brain 
Jayashankar 
et al. [123] 
1.5 mg/kg  
(≈0.007 mM)  
or above 
for 11 weeks including 
gestation period and  
2 weeks post-partum 
Exposure to MeHg chloride or MeHg cysteine altered 
expression of genes involved in functional clusters of 
immunoglobulin, metal/zinc binding, or methylation in 
pup brain 
Glover et al. 
[124] 
Zebrafish 
60 µg/L  
(≈0.3 µM) 48–72 hpf 
Altered expression of clusters of genes involved in 
apoptosis, oxidative stress response, transcriptional 
elongation, or DNA repair 





0.5 mg/kg  
(≈0.002 mM) GD7–PND21 
Altered vertical activity in 2-month old female, but not 
in male rats 
Cauli et al. 
[126] 
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Table 1. Cont. 
Substance Endpoints In Vivo Model Concentration a Exposure Period b Key Observations c References 
  Mouse 
1.5 mg/kg  
(≈0.007 mM) 
for 11 weeks including 
gestation period and  
2 weeks post-partum 
Altered open field activity in pups exposed to MeHg 
chloride, but not MeHg cysteine 





Mouse 0.1 mM GD8–PND21 
Altered expression of genes related to signal 
transduction pathway in female pup brain 
Kasten-Jolly 
et al. [127] 
Zebrafish 
100 ppb  
(≈0.5 µM) 
2–16 cell stage  
−72 hpf 
Altered global expression of genes related to 
neurological development, functioning, or diseases 
Peterson  




100 ppb  
(≈0.5 µM) ≈2–≈36 hpf Decreased density of axon tracts  





5 mg/L  
(≈0.02 mM) 
GD0–60 days of age  
in offspring 
Increased locomotor activity  
Luo et al. 
[129]  
2.84 mg/mL  
(≈14 mM) GD1–PND24 
Maternal Pb exposure did not induce anxiety-related 
behavioral change in pups 
Molina et al. 
[130] 
Zebrafish 
10 nM  
or above 
<2–24 hpf 
Altered startling behavior in response to tapping 
stimulation 
Rice et al. 
[131] 
0.1 mg/L  
(≈0.5 µM)  
or above 
≈6–8 to 20–30 hpf Altered spontaneous movement  
Chen et al. 
[132] 0.025 mg/L  
(≈0.1 µM)  
or above 
6–96 hpf 
Altered swimming activity in response to  
light stimulation 
6–120 hpf Altered swimming activity under light or dark condition 
0.2 mM 0–144 hpf Altered spontaneous swimming activity 
Dou and 
Zhang [133] 
a Concentration of substances tested on animals followed by key observation; b GD, gestational day; hpf, hours post fertilization; PND, post-natal day; c Significance of 
key observations is described in comparison to that of control. 
 




Mercury (Hg) is a common metal that is naturally present in the environment. Hg can also be 
released by human activities such as gold mining or coal burning, which in turn contaminates air, soil, 
and water [134]. In the aquatic environment, Hg accumulates in aquatic biota and biomagnifies 
through the food chain. As a result, animals at the top of the food web (e.g., heavy seafood consumers) 
tend to be exposed to relatively high levels of Hg. Similarly, seafood consumption has also been 
pointed out as a primary source of human exposure to Hg [135,136]. Hg can exist in several oxidation 
states including elemental (Hg0), mercurous (Hg1+), and mercuric mercury (Hg2+). The mercurous and 
mercuric Hg can interact with carbon containing compounds, resulting in the formation of 
methylmercury (MeHg) and ethylmercury. 
Historically, health concerns of CNS exposure to Hg have mainly arisen from exposure to MeHg 
(reviewed in [137,138]). Therefore, the emphasis in much research has been placed on revealing the 
neurotoxicity of MeHg, especially in prenatal and early postnatal organisms. The potent neurotoxic 
effect of MeHg during development is well known from the environmental disaster in Minamata, 
Japan in the mid-1950s. In this early event, maternal consumption of seafood contaminated with high 
levels of MeHg (i.e., umbilical cord blood level at 1 ppm or higher) resulted in the poisoning of the 
fetus (reviewed in [138]). Consequently, the affected infants diagnosed with congenital Minamata 
disease exhibited a variety of neurodevelopmental symptoms (e.g., mental retardation, dysarthria, and 
chorea) with severe damage in the brain cortex and cerebellum (reviewed in [138]). 
In later years, two important cohort studies, the Seychelles Child Development Study (SCDS) and  
a study with the Faroese birth cohort, were conducted to examine the effect of prenatal MeHg exposure 
on the neurodevelopment of children. Both of these studies recruited cohorts of offspring who were 
maternally exposed to MeHg through high-fish diets, but showed dissimilar results. One prospective 
study using the Seychelles cohort started with hair sampling of 779 pregnant women for MeHg 
measurements in 1989–1990 [139]. The measured hair MeHg level, an indicator of maternal MeHg 
exposure, was used for comparison with the offspring’s neurodevelopmental status evaluated by 
applying age appropriate test batteries (e.g., the Bayley Scales of Infant Development and Wechsler 
Intelligence Scale for Children) at 6, 19, 29, 66 and 107 months of age [139]. There are a number of 
publications using the cohort of the SCDS that have followed up on the neurodevelopmental status of 
the test participants (up to 17 years of age in Davidson et al. [140]); however, the clear association 
between maternal MeHg exposure and neurodevelopmental alterations in the affected offspring has not 
been identified [140–143]. 
Another study was performed with a birth cohort in the Faroe Islands that included 1022 children 
born during 1986–1987 [144–147]. In studies using this birth cohort, researchers measured MeHg 
levels in maternal hair and cord blood to estimate the level of prenatal exposure. Offspring were then 
subjected to neurobehavioral tests (e.g., the Boston Naming Test and the California Verbal Learning 
Test) at 7 and 14 years of age [144–147]. Unlike the results shown in the SCDS, children in the 
Faroese Islands exposed to MeHg as a fetus exhibited neurobehavioral alterations, suggesting the 
negative impact of prenatal MeHg exposure on the offspring’s neurodevelopment [144–147]. 
There are also studies reporting new observations that prenatal MeHg exposure may cause damage 
in brain areas involved in the processing of visual information [148,149]. For example, when 102 Inuit 
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children were tested at preschool age, higher plasma MeHg levels in children were associated with 
altered ability of brain visual processing [148]. Similar neuropsychological alterations were also 
reported in teenagers (14 years of age), suggesting that maternal MeHg exposure may have a long 
lasting impact on offspring’s visual information processing capability [149]. 
In addition, nonhuman primate studies have been conducted on the DNT of MeHg [150]. 
Gunderson et al. [151,152] reported that maternal MeHg exposure of non-human primates impaired 
the cognitive ability of their offspring, leading to decreased visual recognition memory in affected 
infants. In Burbacher et al. [153], infant monkeys maternally exposed to MeHg exhibited altered social 
behavior compared to the control monkey offspring. Long-term postnatal exposure to MeHg also 
negatively impacted visual function in monkeys at older ages (≈4 years of age) [154,155]. 
In vivo rodent models developmentally exposed to MeHg exhibited neurobehavioral (e.g., motor 
activity, startle response, learning/memory ability, or activity related with one’s motivation) and/or 
physiological (e.g., brain gene expression, enzymatic activity, or neuronal cell damage)  
changes [124,126,156–165]. Interestingly, the effects of developmental MeHg exposure may be 
different depending on sex or age of test animals at the time of DNT evaluation. As an example, in one 
study, female rat offspring maternally exposed to MeHg (0.5 mg/kg/day, from GD7 until postnatal Day 
21) exhibited a decrease in vertical activity when tested at 2 months of age, while the activity of male 
offspring increased at the age of 3 months [126]. In another study, Beyrouty et al. [157] observed 
abnormal movement in female offspring, but not in males, when mothers were treated with MeHg  
(0.5 mg/kg/day from 4 weeks before mating until GD20) in response to auditory stimulation compared 
to control. Moreover, a significant decrease in monoamine oxidase enzyme activity was also detected 
in the brainstem of female offspring maternally treated with a higher dose of MeHg (1 mg/kg/day), 
while this change of enzymatic activity did not appear significant in male offspring [157]. Studies 
conducted in the past five years on the neurotoxic effects of MeHg exposure with rodent models in 
developmental stages are summarized in Table 1. 
The underlying mechanisms of MeHg DNT are not yet fully understood, but may be associated 
with interference of receptor activities involved in signaling pathways, oxidative stress defense 
mechanism, or the differentiation of the BBB [159,162–165]. 
3.3. Lead 
Lead (Pb) is a metallic element, which occurs naturally in the environment. Pb, with a common 
oxidation state of 2+ or 4+, exists as organic Pb and inorganic Pb, with humans being exposed to both 
forms. Human exposure to Pb increased extensively with its utilization in production of industrial 
chemicals (e.g., as a gasoline additive and in Pb-based paint) during the 1920s–1970s. Since the  
mid-1970s, the addition of Pb for fuel or paint production has been restricted in many of the developed 
countries including the US because of the increasing health concerns associated with Pb exposure on 
various organ systems including the CNS. However, even after the withdrawal, environmental Pb 
exposure is still an ongoing concern in that exposure to low doses of Pb is reported to be associated 
with neurodevelopmental alterations in children [2,3]. 
Neurotoxic consequences of a developmental Pb exposure was noticed as early as the 1970s by 
studies conducted with subjects who were exposed to relatively high levels of Pb (e.g., a mean 
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concentration of 202.1 µg Pb/g dentine) [166,167]. These early studies reported that Pb-exposed 
children exhibited several features of neurodevelopmental deficits including cognitive decline, 
decreased IQ score, and learning disabilities [166,167]. Later, studies with children exposed to much 
lower levels of Pb also detected similar neurodevelopmental deficits [168,169]. One noticeable 
example is a prospective study conducted by Bellinger et al. [168]. In this study, a cohort of  
249 children was categorized into three groups according to their prenatal Pb exposure levels estimated 
by measuring cord blood Pb concentration ranging from below 3 µg/dL though 10 µg/dL or above. 
Bellinger et al. [168] then evaluated the Mental Development Index (of Bayley Scales of Infant 
Development) of subjects included in each of the three groups at different stages of development until 
2 years of age. Subjects prenatally exposed to higher levels of Pb (cord blood Pb level of  
10–25 µg/dL) showed poor performance in the cognitive development test during 2 years of 
development compared to those with lower cord blood Pb levels (below 10 µg/dL), suggesting a 
negative impact of prenatal Pb exposure on early neurodevelopment [168]. 
To date, studies continue to report negative impacts of low-dose Pb exposure (i.e., blood Pb level 
below 10 μg/dL) on early neurodevelopment, leading to lowered IQ, increased ADHD risk, and poor 
academic achievement in children and cognitive decline in infants [2,3,170,171]. Canfield et al. [3] 
measured blood Pb levels of children at age 6–60 months and then examined their IQ scores at age  
3 and 5 years using the Stanford-Binet Intelligence Scale. Researchers found a linear relationship 
between a 4.6-point decline in children’s IQ and every 10 μg/dL increase of blood Pb level using a 
lifetime average [3]. In addition, Braun et al. [2] reported a relationship between a developmental Pb 
exposure at blood Pb levels in children below 10 μg/dL and an increased risk of ADHD. In this study, 
it was shown that children at the ages of 4–15 with higher levels of Pb in the blood (2–5 μg/dL) were 
at a 4.5-fold increased risk for ADHD compared to those with low blood Pb levels (below the limit of 
detection through 0.7 μg/dL) [2]. 
In addition, nonhuman primate studies have also shown the relationship between early-life Pb 
exposure and behavioral alterations [172–175]. For example, in Bushnell and Bowman [172,173], 
developmental Pb exposure resulted in poor performance on reversal learning tasks. In  
Laughlin et al. [176], it was also reported that monkeys developmentally exposed to Pb exhibited 
altered social behavior at an early age. 
A number of mechanisms of Pb DNT have been proposed and while an extensive number of studies 
have been conducted, the mechanisms of Pb DNT are not yet completely understood. To this end, 
several in vivo rodent studies have been performed in immature brains, relating developmental  
Pb exposure with alterations of cholinergic-, catecholaminergic, or glutamatergic neurotransmitter 
systems [177–180]. Several studies have related developmental Pb exposure and the function of 
glutamate receptor or its subtypes (e.g., N-methyl-D-aspartate (NMDA) receptor subtypes and 
metabotropic glutamate receptors) [180–183]. The functional importance of glutamate receptors is 
known with their involvement in excitatory signal transmission and learning/memory function [184]. 
Thus, the focus of many Pb DNT mechanistic studies has been on defining expression alterations of 
glutamate receptors. Accordingly, some progress has been made with studies identifying increased 
sensitivity to NMDA or altered expression of glutamate receptors in brain samples (e.g., the 
hippocampus) following developmental Pb exposure in rat models [180–183]. Studies conducted in the 
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past five years on the neurotoxic effects of Pb exposure with rodent models in developmental stages 
are summarized in Table 1. 
3.4. Mixtures 
There are also several studies completed evaluating DNT of metal mixtures with a specific 
consideration given to mixtures of arsenic, MeHg, or Pb with each other or with other metals such as 
manganese and cadmium [119,185–187] or with organic chemicals such as polychlorinated biphenyls 
and polybrominated diphenyl ethers (PBDEs) [126,188,189]. Combined with the increasing evidence 
in recent years, it has been revealed that developmental exposure to neurotoxic chemical mixtures may 
have additive or synergistic adverse effects. However, the various outcomes and complex mechanisms 
of DNT induced by co-exposure to multiple chemicals still remain largely unknown. 
4. DNT Studies Using the Zebrafish Model System 
4.1. Application of the Zebrafish Model in Various Chemical-Induced DNT Studies 
The zebrafish model has been applied in DNT research using a variety of chemical compounds 
including different classes of pesticides, ethanol, PBDEs, and other emerging environmental contaminants 
(e.g., nanoparticles). These studies have demonstrated DNT of various substances, among which major 
findings highlighting the potential of the zebrafish model, which are introduced in this section. 
Several studies have addressed zebrafish as a suitable model for testing pesticide-induced 
neurotoxicity appearing in very early stages of development [45,46,49,53,57–59,64,65]. Studies on 
organophosphorus pesticides, especially chlorpyrifos, indicated that developmental exposure to this 
chemical induced neurobehavioral changes in the zebrafish [46,57,65]. Eddins et al. [46] examined 
effects of chlorpyrifos exposure on levels of neurochemicals of zebrafish (144 hpf), showing decreased 
dopamine and serotonin levels but not norepinephrine levels. Effects of a developmental chlorpyrifos 
exposure or exposure to the metabolites of chlorpyrifos on acetylcholine esterase (AChE) activity were 
also assessed. In Yen et al. [65], exposure to chlorpyrifos significantly decreased AChE activity of 
zebrafish (120 hpf). On the other hand, in Yang et al. [64], it was the oxon metabolite of chlorpyrifos, 
not chlorpyrifos, which induced a significant decrease in AChE activity (48 and 72 hpf) with alteration 
of swimming activity (72 hpf) in wild-type, and growth inhibition of axons in transgenic zebrafish (72 hpf). 
DNT of pyrethroids and other pesticides (e.g., cartap, fenvalerate, fipronil, thiocyclam) has also 
been tested in the zebrafish model [45,49,53,58,59]. DeMicco et al. [45] observed abnormal movement 
of body, which is described as “spastic movement”, in the zebrafish (96 hpf) developmentally exposed 
to Type I (bifenthrin, permethrin, and resmethrin) or Type II pyrethroids (λ-cyhalothrin, cypermethrin, 
and deltamethrin). Interestingly, body curvature observed in zebrafish (144 hpf) developmentally 
treated by either Type I pyrethroids (bifenthrin and permethrin) or three Type II pyrethroids was  
also explained as an indication of neurotoxicity, not as a result of morphological alteration. This 
interpretation, both the spasms and the curvature as consequences of DNT, turned out to be rational 
since registration of diazepam (a γ-aminobutyric acid [GABA]A receptor antagonist) or MS-222  
(a sodium channel blocker) after deltamethrin treatment alleviated the abnormal movements and/or the 
curvature [45]. In another pyrethroid study, zebrafish exposed to cypermethrin exhibited apoptotic cell 
Toxics 2014, 2  476 
 
 
death (96 hpf) in the CNS region (brain and spinal cord) [58]. Cypermethrin exposure also altered 
activities of enzymes responsive to oxidative stress (i.e., superoxide dismutase and catalase), level of 
malondialdehyde, and expression of a gene involved in DNA repair (i.e., 8-oxoguanine DNA glycosylase 
(ogg1)), suggesting the neurotoxic mechanisms related to the pathways of oxidative stress production 
and DNA-repair [58]. Similar effects were shown in the study of fenvalerate to which exposure 
resulted in apoptosis in the brain region of embryo and larval zebrafish [49]. In this study, changes in 
superoxide dismutase activity and expression of distal-less homeobox 2 (dlx2, a gene involved in 
neural differentiation) as well as ogg1 were observed, implying the involvement of oxidative stress 
generation and alteration of dlx2 and ogg1 related biological processes in mechanisms of  
fenvalerate-induced DNT [49]. 
The zebrafish model has been applied for testing the developmental neurotoxic effects of exposure 
to chemicals related to Parkinson’s disease, including 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP), paraquat, and rotenone [37,62]. It seems clear that MPTP induces neurobehavioral changes 
and/or neuronal decrease in the developing zebrafish [37,43,62]. In Bretaud et al. [37], while paraquat 
or rotenone treatment did not induce significant changes, MPTP exposure induced decreases in 
swimming speed and in the number of dopaminergic neurons in the diencephalon of zebrafish at  
168 hpf and 120 hpf, respectively. Being a well-defined developmental neurotoxicant, MPTP was also 
used as a positive compound by Chen et al. [43] in which sodium benzoate exposure resulted in 
decreased dopamine neuronal expression of tyrosine hydroxylase and dopamine transporter at 72 hpf, 
and altered larval locomotive activity at 144 hpf. 
There are zebrafish studies on ethanol-induced neurotoxicity, showing the effects of developmental 
ethanol exposure on several neurotoxicological endpoints (e.g., altered behavior, apoptotic cell death, 
decreased retino-tectal projection area) and also the underlying mechanism [38,42,48,51]. Especially, 
apoptotic cell death occurring in the head area has been pronounced as one of the neurotoxic  
effects caused by developmental ethanol exposure in the zebrafish [38,48,51]. For example, in  
Flentke et al. [48], ethanol toxicity was investigated in regard to the association between ethanol 
exposure and fetal alcohol spectrum disorders. Flentke et al. [48] showed that ethanol exposure for 3 h 
resulted in apoptotic death of neural crest cells related to the calcium calmodulin-dependent protein 
kinase II signaling pathway. 
Zebrafish studies have revealed the neurotoxic effects of exposure to PBDEs (e.g., DE-71, BDE-47, 
BDE-49), showing alteration in neurobehavior, genetic expression, cholinergic system and/or axonal 
growth [39–41,52]. As an example, in Chen et al. [39], zebrafish (120 hpf) developmentally exposed to 
DE-71 exhibited altered locomotor movement, increased AChE activity, and decreased expression of 
nervous system genes (myelin basic protein, α1-tubulin, and sonic hedgehog a). Parental exposure to 
DE-71 (for 150 days) also induced changes in neurobehavior, CNS gene expression (myelin basic 
protein, synapsin IIa, α1-tubulin), and the cholinergic system but with decreased AChE activity in F1 
offspring at 96 hpf [40]. 
As shown in the research above, the zebrafish has a potential to be applied for testing DNT of a 
broad range of chemicals. However, a limited number of zebrafish studies have been conducted on 
influences of exposure to other substances (e.g., TCDD, cadmium, nanoparticles, and valproate) on 
neurobehavior or neurogenesis in the developmentally exposed zebrafish [42,44,50,54,63,66]. To this 
end, there has been a need to develop the strengths and further the application of the zebrafish as a 
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model organism for DNT testing. Studies have suggested endpoints which can serve as indicators in 
DNT screening of a variety of chemicals, which are described in the below section. 
4.2. The Zebrafish as a Potential Tool for Chemical-Induced DNT Screening 
The zebrafish model allows screening of multiple chemical DNT within a few days through 
examination of cellular (apoptosis) or specific neuronal proliferation (neuronal development or survival) 
appearing in the brain region by utilizing simple staining methods such as acridine orange (AO) 
staining or immunostaining [60,61]. For example, Ton et al. [61] suggested the zebrafish as a screening 
tool for DNT assessment, showing that measurement of cell death in the brain can be a useful endpoint 
using the zebrafish in the early life stage (96 hpf). Zebrafish were treated with five test chemicals (e.g., 
atrazine, 2,4-D, DDT, dieldrin, and nonylphenol), one teratogen (TCDD), or one negative compound 
for neurotoxicity (malathion) and then axonal tracts, catecholaminergic neurons, and apoptotic cell 
death occurring in the brain region visualized [61]. DNT was differentiated from teratogenic effects by 
obtaining the teratogenic index of each chemical. The results specified 2,4-D, dieldrin, and 
nonylphenol as developmental neurotoxicants among the seven chemicals tested [61]. 
Fan et al. [47] and Cowden et al. [42] suggested the examination of the quantitative expression of 
selected genes or the retino-tectal projection area as potential DNT endpoints. The relevance of these 
endpoints was proven using ethanol and/or valproate as model neurotoxicants. Fan et al. [47] provided 
gene expression profiles of ten nervous system genes (e.g., glial fibrillary acidic protein, myelin basic 
protein, nestin, synapsin IIa) with control genes (ribosomal protein L13A and elongation factor1 alpha) 
during zebrafish development (≈6 days), so that this information can be used for future DNT screening. 
Neurobehavioral alterations are a popular neurotoxicological endpoint in DNT studies using the 
zebrafish. With the small size, transparency, and ex vivo embryonic development of the zebrafish, live 
tracking of zebrafish behaviors using video recording tools is available from the early embryonic 
stages. A recent study by Kalueff et al. [190] further defined major behaviors of zebrafish to aid in the 
interpretation of zebrafish behavioral changes as phenotypes of neurological alterations. In the field of 
DNT research, the zebrafish neurobehavioral changes observed as endpoints can be grossly divided 
into three categories: spontaneous movement, touch-responsive movement, and locomotor activity 
induced without touch stimulation. These endpoints have been the basis for the development of 
methods for screening chemical-induced DNT in recent studies [42,55,56]. For example, as an attempt 
to provide a method for DNT screening using zebrafish, Selderslaghs et al. [56] examined behaviors of 
embryos (spontaneous movement) and larvae (swimming activity). These neurobehavioral endpoints 
were observed following exposure to seven chemicals with known DNT (e.g., acrylamide, bisphenol A, 
chlorpromazine, or MeHg) or three negative substances (e.g., acetaminophen, omeprazole, or saccharin). 
These results were then compared to the existing literature on the DNT of these chemicals [56]. Test 
results using all chemicals but omeprazole corresponded to existing animal data, showing the potential 
of the zebrafish in early life stages as a tool for screening chemical-induced DNT [56]. 
Overall with the recent gains in knowledge on zebrafish neurobehavior and transcriptional 
regulation, behavioral assays and transcriptional assessments provide comparable DNT data to 
traditional rodent model studies. Furthermore, various strengths of the zebrafish are being utilized to 
further the understanding of DNT at endpoints that are not as easily assessed in rodent models. For 
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example, the ex vivo embryonic development allows microscopic examination of developing axons 
immediately after fertilization, serving as a valuable indicator of DNT which is not as easily assessed 
in other vertebrate model systems. 
4.3. DNT Studies of Arsenic, Methylmercury, or Lead Using the Zebrafish 
The zebrafish has been utilized in several studies on the DNT of arsenic, MeHg, and Pb (Table 1). 
In these studies, the neurotoxic consequences of developmental metal exposures and/or the underlying 
mechanisms of metal DNT have been investigated from various angles (e.g., axonal growth inhibition, 
transcriptomic alterations, or neurobehavioral changes). In this section, we review the progress made 
in DNT studies on the metalloid arsenic and the two metals MeHg and Pb using the zebrafish as a test 
organism to support further studies of DNT using this model system. As an effort to differentiate 
developmental toxicity from DNT, overt signs of toxicity such as altered hatchability of embryo, 
lethality, or gross morphological (e.g., craniofacial alteration) or histological (e.g., organ edema) 
changes are excluded from the review unless the neurotoxic origin of those effects are clarified. 
There are a few studies describing the effects or mechanisms of neurotoxicity associated with a 
developmental exposure to arsenic. In a study by Li et al. [120], zebrafish embryos were exposed to 
either a control treatment or various concentrations of sodium arsenite from 4 hpf. To investigate the 
effects of arsenite exposure on early neurodevelopment, the zebrafish embryos were subjected to either 
simple microscopic observations at 30 hpf or immunostaining at 48 hpf [120]. The former experiment 
was conducted to observe the reflexive actions of embryos in response to light stimulation, revealing 
that the frequency of motions made by embryos developmentally treated with 2 or 5 mM arsenite 
decreased significantly compared to the control zebrafish [120]. As the zebrafish in very early stages 
of development has a relatively simple neuronal network, the observation of the reflexive movement 
may reflect the altered neuronal function derived from arsenite exposure, not the secondary outcome of 
non-DNT (e.g., growth retardation). In the immunostaining experiment, axonal tracts of zebrafish 
embryos were visualized using acetylated α-tubulin (α-AT) antibody and showed altered growth 
patterns of axons in the brain and spinal cord of zebrafish exposed to 2 mM of arsenite compared  
to those in the control treatment [120]. Furthermore, researchers also found that exposure to 2 mM 
arsenite induced changes in patterns of cell proliferation, cell death, and DNA methylation in 
developing zebrafish at 24 and/or 48 hpf using various methods including proliferating cell nuclear 
antigen (PCNA) labeling, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
assay, and 5-methylcytidine labeling [120]. Based on these observations, it might be reasonable to 
assume that arsenite DNT is related to the altered biological processes strictly regulated by proper cell 
proliferation, apoptosis, or DNA methylation during normal embryonic development. To generalize 
this assumption, however, additional investigations into the molecular mechanism of arsenite DNT 
need to be performed to clarify that the effects observed in the zebrafish are the consequences of DNT 
and not of teratogenicity. A follow-up study by Li et al. [191] investigated the mechanisms of arsenic 
DNT with a focus on the activity of zebrafish Dvr1, which is involved in axis formation (known as 
growth differentiation factor 1 (GDF1) in mammals). In this study, quantitative polymerase chain 
reaction (qPCR) and whole mount in situ hybridization techniques were utilized to detect the levels of 
Dvr1 expression in the developing zebrafish. The results of this study showed a decrease in Dvr1 
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expression in 2 mM sodium arsenite treated embryos compared to those in the control group at 6 hpf in 
both of the experiments [191]. To further investigate the association between Dvr1 function and early 
development of the zebrafish nervous system, researchers injected a Dvr1 morpholino (MO) with or 
without plasmids encoding Dvr1 homolog (e.g., mouse GDF1) [191]. By performing this simple MO 
injection into the embryo, expression of a specific gene of interest can be silenced in the zebrafish.  
The generated Dvr1 morphants were then subjected to α-AT staining at 48 hpf and showed impaired 
neural development in the brain, trunk, and tail compared to embryos in the control treatment  
(i.e., not genetically manipulated embryos) [191]. In the same immunostaining experiment using 
embryos co-treated with Dvr1 MO and plasmids, the expression of mouse GDF1 alleviated the 
neurodevelopmental effects of Dvr1 knockdown, suggesting the involvement of Dvr1 in the mechanism 
of arsenic DNT in the zebrafish [191]. 
Long et al. [192] identified the expression of abcc5 (ATP-binding cassette transporter), which plays 
a role in cellular signaling and protection from xenobiotics, in the zebrafish embryo with or without an 
exposure to heavy metals including arsenic, mercury, and Pb. Firstly, Long et al. [192] characterized 
quantitative and spatial expression of abcc5 by using qPCR and whole mount in situ hybridization, 
revealing that abcc5 was expressed in the lens and brain during embryogenesis (24, 48, and 72 hpf). 
The level of abcc5 expression was then evaluated in embryos treated with different concentrations of 
metals, including sodium arsenate (100 µM), Hg chloride (0.5 µM), or Pb nitrate (50 µM) [192]. qPCR 
results indicated that each metal exposure (through 24 to 48 hpf) resulted in a significant increase in 
quantitative abcc5 expression [192]. The pattern of abcc5 expression observed without metal exposure 
implies that this gene may have a role in distinctive regions including the brain during embryogenesis. 
Although it needs to be further elucidated, considering the function of abcc5 is to transport cGMP in 
signal transduction, one can speculate that expression alterations of abcc5 induced by metal exposure 
may interfere with important biological processes such as neurodevelopment. 
The zebrafish model system was also applied to investigate MeHg DNT. Hassan et al. [193] 
observed a significant reduction of cellular proliferation occurring in the neural tube of zebrafish 
developmentally exposed to 10, 50, or 80 µg/L (≈0.4 µM) MeHg at 30 hpf using PCNA staining. 
Cuello et al. [194] investigated the effects of MeHg exposure on zebrafish development at the protein 
level using iTRAQ (isobaric tags for relative and absolute quantification). Altered expression of 
proteins involved in calcium binding (e.g., parvalbumin-2 and parvalbumin 9, and parvalbumin 
isoform 1d) was observed in the zebrafish treated with 25 µg/L (≈0.1 µM) MeHg from 72 to 144 hpf, 
suggesting the disturbance of calcium homeostasis as an important mechanism of MeHg toxicity. More 
recently, Ho et al. [125] treated embryos with 60 µg/L (≈0.3 µM) MeHg from 48 to 72 hpf and then 
conducted microarray analysis, which enables global detection of gene expression changes in the 
zebrafish. Researchers then conducted a whole mount in situ hybridization with 88 genes that showed 
substantial expression changes in the microarray analysis and confirmed expression alterations of 60 of 
the 88 genes [125]. The data from the in situ hybridization experiments also allowed further grouping 
of genes according to their expression patterns shown in different tissues. In this analysis, 24 of the  
88 genes had specific expression alterations in the brain region [125]. These 24 genes expressed in  
the brain were involved in a variety of biological activities including transcriptional regulation, 
development, and transport processes, implying possible biological disturbances in the zebrafish brain 
affected by developmental MeHg exposure [125]. The information obtained from this transcriptomic 
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analysis is valuable since there is a lack of basic data about potential molecular targets of MeHg 
neurotoxicity. Thus, this data can assist in identifying targets for later in-depth studies using the 
zebrafish to further define the molecular mechanisms of MeHg DNT toxicity. 
Several Pb DNT studies have been carried out using the zebrafish, presenting various signs of 
neurodevelopmental alterations in Pb exposed subjects (reviewed in [195]). Low concentrations tested 
in the Pb exposure studies described below show that the zebrafish is indeed a very sensitive in vivo 
test model for DNT assessment. For example, Peterson et al. [128] evaluated global gene expression 
changes in developing zebrafish in response to a low-dose Pb exposure. Microarray analysis was 
performed with embryos treated with 100 ppb (≈0.5 µM) Pb through the end of embryogenesis, 
resulting in significant expression alterations of 55 genes engaged in processes related to nervous 
system development/functioning and neurological diseases [128]. Western blot analysis revealed 
significant changes in expression of several target proteins including metallothionein-2, FRY-like, and 
reelin [128]. The results of this study are noteworthy in revealing that a low-dose of Pb was sufficient 
to induce expression alterations of genes/proteins involved in the zebrafish nervous system. In addition, 
it is also important to note that the alterations detected at 72 hpf were not present at 120 hpf, implying 
that the effects of a developmental Pb exposure might be time point specific. It is yet unclear whether 
the expression alterations of nervous system genes observed at 72 hpf are reflective of transient effects 
of Pb exposure or not. To answer this question, further analyses of global changes of gene expression 
appearing at stages earlier than 72 hpf and later than 120 hpf need to be performed. 
In a follow-up study, Peterson et al. [196] assessed the expression of zebrafish reln (equivalent to 
human reelin that is known to be involved in neuronal development and diseases). Zebrafish embryos 
were exposed to up to 100 ppb Pb acetate shortly after fertilization through 24–96 hpf, and then 
subjected to whole mount in situ hybridization or qPCR analysis to evaluate expression alteration of 
zebrafish reln [196]. In the in situ hybridization experiment, expression of reln was noticeable in the 
CNS region beginning at 24 hpf, while no spatial expression alterations were observed in response to 
the Pb exposure. A significant decrease in reln expression occurred only in embryos treated with  
100 ppb Pb at 60 hpf, without significant changes in brain morphology or brain cell apoptosis.  
These findings suggest a time point specific role of this gene that might be involved in neurotoxic 
mechanisms other than brain morphogenesis [196]. Considering the absence of apoptotic cell death in 
the brain, which is one of the frequently used indicators of neurotoxicity in zebrafish studies, focus of 
future studies needs to be placed on different mechanisms of neurotoxicity. 
In an additional follow-up study, the effect of Pb exposure on axonal growth in the developing 
zebrafish was studied following exposure to 100 ppb Pb acetate at several time points between  
18–36 hpf by α-AT staining and showed a significant decrease in axonal density in Pb exposed 
embryos at 18, 20, or 24 hpf [70]. The genetic mechanisms underlying this Pb-induced axonal density 
decrease were investigated by measuring quantitative expression of genes involved in axon guidance in 
embryos exposed to 100 ppb Pb through 14–36 hpf. The qPCR analysis revealed that expression of 
sonic hedgehog a and ephrin type-A receptor 4b were significantly down-regulated at 14 and 16 hpf, 
respectively [70]. On the other hand, netrin2 expression increased significantly at 30 and 36 hpf, 
suggesting the involvement of netrin2 in regulating axonal growth in response to Pb neurotoxicity at 
early developmental stages [70]. 
Toxics 2014, 2  481 
 
 
Recently Wirbisky et al. [69] investigated the effects of Pb acetate exposure (up to 100 ppb, up to 
72 hpf) on the GABAergic system of embryonic zebrafish using qPCR and High Performance Liquid 
Chromatography (HPLC). In the qPCR analysis, Pb treated embryos exhibited time point specific 
expression alterations of genes involved in GABA production (gad2, gad1b), transport  
(gat-1, gat-3, vgat), and GABA receptors (gabra1, gabbr1a) throughout embryogenesis [69]. GABA 
measurement by HPLC revealed that embryonic Pb exposure also induced fluctuation of GABA levels 
with an increase in GABA at 48 hpf and a decrease in GABA at 72 hpf [69]. These results suggest that 
Pb exposure interferes with the GABAergic system in the zebrafish during embryonic developmental 
stages with different patterns of genetic expression and GABA level fluctuations. In regards to the 
function of GABA which can be either excitatory or inhibitory at different embryonic developmental 
stages, future observations at narrower ranges of developmental time points may explain the 
importance of the GABAergic system as a mechanism of Pb-induced DNT. 
Developmental Pb exposure also causes neurobehavioral changes in the zebrafish. In Rice et al. [131], 
embryos were treated with up to 30 nM of Pb chloride through 24 hpf and then subjected to a 
neurobehavioral test at 168 hpf. The behavioral changes of the zebrafish were evaluated on several 
parameters reflecting altered movement in response to different frequencies of tapping stimulation  
(i.e., one tap/s or four taps/s), showing that zebrafish developmentally treated with 30 nM of Pb 
exhibited altered responses under both the one and four taps/second frequency stimulation [131].  
Rice et al. [131] also provided a probable mechanistic interpretation of the behavioral changes 
including altered sensitivity of mechanosensory neuromasts, function of neurons involved in signal 
integration, or neurotransmitter signaling, albeit inclusive. In another study Chen et al. [132] treated 
zebrafish with up to 1 mg/L (≈5 µM) Pb acetate from 6–8 hpf and monitored spontaneous movement 
from 20 until 30 hpf, showing that spontaneous activity of embryos exposed to 1 mg/L of Pb 
significantly decreased at most of the tested time points. Chen et al. [132] also examined behavioral 
changes of zebrafish developmentally treated with lower concentrations of Pb acetate (up to 0.1 mg/L 
(~0.5 µM)) starting from 6 hpf until the time of evaluation. In the test conducted under constant light 
or dark condition at 120 hpf, zebrafish developmentally exposed to 0.1 mg/L Pb showed a significant 
decrease and increase in mean swimming speed under light and dark condition, respectively [132].  
The mechanisms of Pb DNT causing the inconsistent change of larval swimming activity as well as the 
alteration of spontaneous movement are largely unknown. Considering the sensitivity of the zebrafish 
embryo and larva, further elucidation may be necessary to discriminate the behavioral alteration 
caused by different experimental conditions from the Pb-induced neurobehavioral effects. Taken 
together, the Pb DNT studies using the zebrafish model have shown the neurotoxic effects of a  
low-dose Pb exposure at specific time points. Information about molecular targets of Pb DNT in the 
zebrafish allows further investigation of mechanisms involved in Pb-induced DNT. Future studies on 
behavioral phenotypes and underlying molecular mechanisms at expanded developmental time points 
or with lower doses of Pb will aid in the understanding of Pb DNT in the zebrafish. 
5. Conclusions 
The zebrafish has traditionally been a popular model in the field of developmental biology with 
current expansion into all areas of biological research. The zebrafish presents a number of strengths  
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as an in vivo laboratory model including the use as a complementary vertebrate model for DNT 
assessment. Furthermore, the application of the zebrafish as a complementary model in DNT studies is 
supported by published studies investigating the DNT of the known neurotoxicants arsenic, MeHg, and 
Pb. To facilitate the application of the zebrafish model in DNT testing, further studies need to be 
conducted on exposure kinetics of various substances to determine exposure doses per embryo or larva. 
A few studies have started to include this analysis (e.g., [69,70]), but more work is needed in this area 
to understand dose and exposure kinetics. In addition, chorionation or dechorionation status at  
the time of chemical exposure may also affect the degree of chemical absorption by the embryo. 
Additionally, there is a need for validation of existing endpoints to distinguish DNT from 
developmental toxicity (e.g., differentiation of behavior from neurobehavior) and for the development 
of novel markers which can be used as direct indicators of DNT in the zebrafish. Overall, with future 
investigations, the use of the zebrafish model system will assist in the screening of developmental 
neurotoxicants and ultimately facilitate our understanding of DNT mechanisms. 
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